A Phase II, Double-blind, Placebo-Controlled, Randomized, Dose-ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40(CNTO1275) in Subjects With Relapsing-remitting Multiple Sclerosis
收藏DataCite Commons2025-06-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008288/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to evaluate the effectiveness and safety of CNTO 1275 in patients
with Multiple Sclerosis
提供机构：
Vivli
创建时间：
2022-07-20
